Dual CAR-T cells
AssigneeCellectis
InventorsAndré Choulika, Laurent Poirot, Beatriz Aranda Orgilles, Philippe Duchateau
Life of this patent
Estimating the term…
Abstract
The present invention concerns new engineered immune cells expressing two CARs directed against two different targets, polynucleotides for preparing said immune cells, pharmaceutical compositions comprising said immune cells, and the use of said immune cells in the treatment of cancers.
Claims26
A genetically engineered immune cell expressing a Chimeric Antigen Receptor (CAR) specific for CD22 (CAR22) and a Chimeric Antigen Receptor specific for CD20 (CAR20) at its cell surface,
- wherein said CAR22 and said CAR20 are encoded by an exogenous nucleic acid incorporated in the genome of said immune cell, and wherein said exogenous nucleic acid comprises, from 5′ to 3′:
- i) a promoter,
- ii) a nucleic acid encoding said CAR20,
- iii) a nucleic acid encoding a self-cleaving peptide, and
- iv) a nucleic acid encoding said CAR22,
- whereby the same promoter controls the expression of said CAR20 and said CAR22, and
- wherein said exogenous nucleic acid comprises the nucleotide sequence of SEQ ID NO:
- 32.
An isolated polynucleotide comprising, from 5′ to 3′:
- a) a promoter that controls the expression of a CAR20, followed by a nucleic acid encoding said CAR20;
- and
- b) a nucleic acid encoding a CAR22,
- wherein said nucleic acids of a) and b) are on a single nucleic acid molecule, and wherein a nucleic acid sequence encoding a self-cleaving peptide is located between said nucleic acids of a) and b), and wherein said single nucleic acid molecule comprises the sequence of SEQ ID NO:
- 32.
A genetically engineered immune cell expressing a Chimeric Antigen Receptor (CAR) that specifically binds to CD20 (CAR20) and a CAR that specifically binds to CD22 (CAR22) at its cell surface, wherein:
- (a) said CAR20 comprises the amino acid sequence of SEQ ID NO:
- 18, optionally without the leader sequence of SEQ ID NO:
- 1;
- (b) said CAR22 comprises the amino acid sequence of SEQ ID NO:
- 14, optionally without the leader sequence of SEQ ID NO:
- 1;
- (c) said genetically engineered immune cell comprises at least one allele encoding TCR alpha, TCR beta, or CD3 that has been inactivated;
- (d) said genetically engineered immune cell has at least one inactivated CD52 allele;
- and
- (e) said CAR20 and said CAR22 are encoded by an exogenous nucleic acid incorporated in the genome of said genetically engineered immune cell, wherein said exogenous nucleic acid comprises SEQ ID NO:
- 32.
Dependencies are inferred from the claim text.